Company Filing History:
Years Active: 2023-2025
Title: Innovations by Sandra Bosshard
Introduction
Sandra Bosshard is a notable inventor based in Plan-les-Ouates, Switzerland. She has made significant contributions to the field of biopharmaceutical manufacturing, particularly through her innovative research and patents. With a total of two patents to her name, her work focuses on enhancing the safety and efficiency of mammalian cell lines used in protein production.
Latest Patents
Bosshard's latest patents include groundbreaking research on the characterization and inactivation of endogenous retroviruses in Chinese hamster ovary (CHO) cells. Her work on type-C endogenous retroviruses (ERVs) embedded in CHO cells has led to modifications that alter the release of retroviral and retroviral-like particles in culture supernatants. Although the infectivity of these particles remains unproven, their presence has raised safety concerns in biopharmaceutical applications. Through her research, she identified 173 type-C ERV sequences that clustered into functionally conserved groups. Notably, she utilized CRISPR-Cas9 genome editing to disrupt the gag gene of the expressed ERV group, leading to a significant reduction in viral RNA-containing particles without compromising cell growth or recombinant protein production. This innovative approach provides a new strategy for mitigating potential contaminations from CHO endogenous retroviruses during biopharmaceutical manufacturing.
Career Highlights
Throughout her career, Sandra Bosshard has worked with prominent companies in the biotechnology sector, including Selexis S.A. and Selexis S.A. Her expertise in the field has positioned her as a key figure in advancing biopharmaceutical manufacturing processes.
Collaborations
Bosshard has collaborated with notable professionals in her field, including Pierre-Olivier Duroy and Philippe Le Mercier. These collaborations have further enhanced her research and contributions to the industry.
Conclusion
Sandra Bosshard's innovative work in the field of biopharmaceutical manufacturing has led to significant advancements in the safety and efficiency of mammalian cell lines. Her contributions through her patents reflect her commitment to improving biopharmaceutical processes and ensuring product safety.